Phase II, open-label study of brivanib as second-line therapy in patients with advanced hepatocellular carcinoma

Clinical Cancer Research

Volumn 18, Issue 7, 2012, Pages 2090-2098

  Finn, Richard S ^a   Kang, Yoon Koo ^b   Mulcahy, Mary ^e   Polite, Blase N ^f   Lim, Ho Yeong ^c   Walters, Ian ^g   Baudelet, Christine ^g   Manekas, Demetrios ^g   Park, Joong Won ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b University of Ulsan   (South Korea)

^c Sungkyunkwan University   (South Korea)

^d National Cancer Center   (South Korea)

^e NORTHWESTERN UNIVERSITY   (United States)

^f UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^g BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; BRIVANIB; COLLAGEN TYPE 4; DOXORUBICIN; SORAFENIB; TUMOR MARKER; AFP PROTEIN, HUMAN; ALANINE; BRIVANIB ALANINATE; DRUG DERIVATIVE; TRIAZINE DERIVATIVE;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ANTIANGIOGENIC THERAPY; ARTICLE; BACKACHE; CANCER CONTROL; CANCER SURVIVAL; CLINICAL ARTICLE; CONSTIPATION; COUGHING; DECREASED APPETITE; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSPEPSIA; DYSPHONIA; FATIGUE; FEMALE; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; HYPONATREMIA; HYPOTHYROIDISM; INOPERABLE CANCER; LIVER CELL CARCINOMA; MALE; METASTASIS; MULTICENTER STUDY; MUSCULOSKELETAL PAIN; NAUSEA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SIDE EFFECT; STOMATITIS; THROMBOCYTE COUNT; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; UPPER ABDOMINAL PAIN; VOMITING; WEIGHT REDUCTION; APPETITE; BLOOD; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; DRUG EFFECT; LIVER TUMOR; MIDDLE AGED; ORAL DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ALANINE; ALPHA-FETOPROTEINS; APPETITE; CARCINOMA, HEPATOCELLULAR; COLLAGEN TYPE IV; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FATIGUE; FEMALE; HUMANS; HYPERTENSION; LIVER NEOPLASMS; MALE; MIDDLE AGED; NAUSEA; TREATMENT OUTCOME; TRIAZINES; YOUNG ADULT;

EID: 84857008164     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-1991     Document Type: Article

References (34)

1. World Health Organization: The global burden of disease. 2004 update. 2010. [accessed 2011 July 15]. Available from: http://www.who.int/healthinfo/ global-burden-disease/GBD-report-2004update-full.pdf.
2. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002.CA Cancer J Clin 2005;55:74-108. (Pubitemid 40372904)
3. Yang ZF, Poon RT. Vascular changes in hepatocellular carcinoma. Anat Rec (Hoboken) 2008;291:721-34.
4. Mathonnet M, Descottes B, Valleix D, Labrousse F, Denizot Y. VEGF in hepatocellular carcinoma and surrounding cirrhotic liver tissues. World J Gastroenterol 2006;12:830-1. (Pubitemid 43380777)
5. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-90.
6. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009;10:25-34.
7. Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 2008;8:592-603.
8. Paez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Viñals F, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009;15:220-31.
9. Finn RS. Development of molecularly targeted therapies in hepatocellular carcinoma: where do we go now? Clin Cancer Res 2010;16:390-7.
10. Cheng A, Kang Y, Lin D, Park P, Kudo M, Qin S, et al. Phase III trial of sunitinib (Su) versus sorafenib (So) in advanced hepatocellular carcinoma (HCC). J Clin Oncol 2011;29(suppl; abstr 4000).
11. Korc M, Friesel RE. The role of fibroblast growth factors in tumor growth. Curr Cancer Drug Targets 2009;9:639-51.
12. Takahashi JA, Mori H, Fukumoto M, Igarashi K, Jaye M, Oda Y, et al. Gene expression of fibroblast growth factors in human gliomas and meningiomas: demonstration of cellular source of basic fibroblast growth factor mRNA and peptide in tumor tissues. Proc Natl Acad Sci U S A 1990;87:5710-14.
13. Javerzat S, Auguste P, Bikfalvi A. The role of fibroblast growth factors in vascular development. Trends Mol Med 2002;8:483-9.
14. Lindner V, Majack RA, Reidy MA. Basic fibroblast growth factor stimulates endothelial regrowth and proliferation in denuded arteries. J Clin Invest 1990;85:2004-8. (Pubitemid 20192979)
15. Ohta T, Yamamoto M, Numata M, Iseki S, Tsukioka Y, Miyashita T, et al. Expression of basic fibroblast growth factor and its receptor in human pancreatic carcinomas. Br J Cancer 1995;72:824-31.
16. Poon RT, Ng IO, Lau C, Yu WC, Fan ST, Wong J. Correlation of serum basic fibroblast growth factor levels with clinicopathologic features and postoperative recurrence in hepatocellular carcinoma. Am J Surg 2001;182:298-304. (Pubitemid 32918381)
17. Ueba T, Nosaka T, Takahashi JA, Shibata F, Florkiewicz RZ, Vogelstein B, et al. Transcriptional regulation of basic fibroblast growth factor gene by p53 in human glioblastoma and hepatocellular carcinoma cells. Proc Natl Acad Sci U S A 1994;91:9009-13.
18. Uematsu S, Higashi T, Nouso K, Kariyama K, Nakamura S, Suzuki M, et al. Altered expression of vascular endothelial growth factor, fibroblast growth factor-2 and endostatin in patients with hepatocellular carcinoma. J Gastroenterol Hepatol 2005;20:583-8. (Pubitemid 40755271)
19. Kerbel RS, Ebos JM. Peering into the aftermath: the inhospitable host? Nat Med 2010;16:1084-5.
20. Siegel AB, Olsen SK, Magun A, Brown RS Jr. Sorafenib: where do we go from here? Hepatology 2010;52:360-9.
21. Batchelor TT, Sorensen AG, di Tomaso E, Zhang WT, Duda DG, Cohen KS, et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 2007;11:83-95. (Pubitemid 46075199)
22. Kopetz S, Hoff PM, Eng C, Overman MJ, Glover KY, Chang DZ, et al. Angiogenic cytokines are increased prior to disease progression in metastatic colorectal cancer patients treated with bevacizumab. Presented at: ASCO Gastrointestinal Cancers Symposium, January 15-17, 2009; San Francisco, CA. Abstract 292.
23. Allen E, Walters IB, Rivera IC, Hanahan D. Anti-angiogenic therapy using brivanib, a combined VEGF and FGF pathway inhibitor, in a mouse model of pancreatic neuroendocrine cancer (PNET), results in sustained vascular blockade, without evidence for evasive/acquired resistance in the form of VEGF-independent revascularization, in contrast to other VEGF inhibitors. Mol Cancer Ther 2009;8:B16.
24. Bhide RS, Lombardo LJ, Hunt JT, Cai ZW, Barrish JC, Galbraith S, et al. The antiangiogenic activity in xenograft models of brivanib, a dual inhibitor of vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinases. Mol Cancer Ther 2010;9:369-78.
25. Cai ZW, Zhang YZ, Borzilleri RM, Qian L, Barbosa S, Wei D, et al. Discovery of brivanib alaninate ((S)-((R)-1-(4-(4-Fluoro-2-methyl-1H-indol-5- yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-yl) 2-aminopropanoate), a novel prodrug of dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinase inhibitor (BMS-540215). J Med Chem 2008;51:1976-80. (Pubitemid 351438880)
26. Marathe PH, Kamath AV, Zhang Y, D'Arienzo C, Bhide R, Fargnoli J. Preclinical pharmacokinetics and in vitro metabolism of brivanib (BMS-540215), a potent VEGFR2 inhibitor and its alanine ester prodrug brivanib alaninate. Cancer Chemother Pharmacol 2009;65:55-66.
27. Mekhail T, Masson E, Fischer B, Gong J, Iyer R, Gan J, et al. Metabolism, excretion, and pharmacokinetics of oral brivanib in patients with advanced or metastatic solid tumors. Drug Metab Dispos 2010;38:1962-6.
28. Wang X, Syed S, Masson E, Walters IB, Roy A, Zhang L, et al.Characterization of brivanib pharmacokinetics in Asian and non-Asian subjects with advanced or metastatic solid tumors. Presented at: Asian Pacific Association for the Study of the Liver (APASL), April 13-16, 2009; Hong Kong. Abstract PE256.
29. Park JW, Finn RS, Kim JS, Karwal M, Li RK, Ismail F, et al. Phase II, open-label study of brivanib as first-line therapy in patients with advanced hepatocellular carcinoma. Clin Cancer Res 2011;17:1973-83.
30. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010;30:52-60.
31. Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX, et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008;100:698-711.
32. Ayers M, Fargnoli J, Lewin A, Wu Q, Platero JS. Discovery and validation of biomarkers that respond to treatment with brivanib alaninate, a small-molecule VEGFR-2/FGFR-1 antagonist. Cancer Res 2007;67:6899-906. (Pubitemid 47105537)
33. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16.
34. Edeline J, Boucher E, Rolland Y, Vauléon E, Pracht M, Perrin C, et al. Comparison of tumor response by response evaluation criteria in solid tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma. Cancer 2012;118:147-56.